CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday's session after the company received positive feedback from the FDA regarding their cancer immunotherapy, Multikine, for treating newly diagnosed advanced primary head and neck cancer patients.
Based on strong safety and efficacy data from a Phase 3 study, the FDA agreed to a confirmatory Registration Study with only 212 participants. Multikine-treated patients in the prior study showed a significant 5-year survival benefit compared to the control group.
The FDA accepted pre-surgical patient selection criteria and study design, recognizing the high unmet need for improved therapies in this population. With a de-risked value proposition, CEL-SCI aims to confirm the positive results in a smaller study and potentially add Multikine to the standard of care for this target population.
How To Buy CVM Stock
By now you're likely curious about how to participate in the market for CEL-SCI – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of CEL-SCI, which is trading at $2.12 as of publishing time, $100 would buy you 47.17 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, CVM has a 52-week high of $3.23 and a 52-week low of $1.04.